Clinical safety and efficacy assessment of the CD137 agonist urelumab alone and in combination with nivolumab in patients with hematologic and solid tumor malignancies Meeting Abstract
| Authors: | Massarelli, E.; Segal, N. H.; Ribrag, V.; Melero, I.; Gangadhar, T. C.; Urba, W.; Schadendorf, D.; Ferris, R. L.; Houot, R.; Morschhauser, F.; Logan, T.; Luke, J. J.; Sharfman, W.; Barlesi, F.; Ott, P. A.; Mansi, L.; Kummar, S.; Salles, G.; Carpio, C.; Meier, R.; Krishnan, S.; McDonald, D.; Maurer, M.; Gu, X.; Neely, J.; Suryawanshi, S.; Levy, R.; Khushalani, N. |
| Abstract Title: | Clinical safety and efficacy assessment of the CD137 agonist urelumab alone and in combination with nivolumab in patients with hematologic and solid tumor malignancies |
| Meeting Title: | 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 4 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2016 Nov 9-13 |
| Meeting Location: | National Harbor, MD |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2016-11-16 |
| Start Page: | 82 |
| Language: | English |
| DOI: | 10.1186/s40425-016-0172-7 |
| PROVIDER: | manual |
| Notes: | Meeting Abstract: O7 |
